Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 53c
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $244.00 +0.12%
EPS Growth %: -20.4%
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
RCBC, GASS, YSG, More
EPS Growth %: -20.4%
Financial Fact:
Income from operations: 136.25M
Today's EPS Names:
RCBC, GASS, YSG, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $5.30, $0.53 better than the analyst estimate of $4.77. Revenue for the quarter came in at $1.02 billion versus the consensus estimate of $1 billion.
GUIDANCE:
Jazz Pharmaceuticals sees FY2024 EPS of $19.20-$20.30, versus the consensus of $18.51. Jazz Pharmaceuticals sees FY2024 revenue of $4-4.1 billion, versus the consensus of $4.05 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Yen Jumps More Than 1% To Trade At 158.22 Per Us Dollar
- Credo Technology Group Holding (CRDO) Tops Q1 EPS by 4c; offers guidance
- Scotiabank Starts SoFi Technologies (SOFI) at Sector Outperform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
